

Clinical Management Protocol – Chemotherapy – Chronic Myeloid Leukaemia

Protocol for Planning and Treatment

The process to be followed when a course of chemotherapy is required to treat:

CHRONIC MYELOID LEUKAEMIA

Patient information given at each stage following agreed information pathway

1. DIAGNOSIS Diagnosis of CML must be confirmed by cytogenetics (Philadelphia chromosome) or PCR (bcr-abl transcripts). All patients must be discussed at the haematology MDT.
2. STAGING N/A
3. HISTOPATHOLOGY N/A
4. INVESTIGATIONS As above
5. RADIOTHERAPY SURGERY N/A
6. CHEMOTHERAPY First line: Imatinib Second line: Dasatinib or Nilotinib Appropriate patients should be offered entry into current clinical trial (SPIRIT2) comparing imatinib against dasatinib for first line treatment.

This document is uncontrolled when printed

File Name: LK-02	Page 1 of 2	Date of Issue: July 2010 Review Date: July 2012
Issue No.: 01/10	Written by: Dr K Gelly	Authorised by: OHMMG

Clinical Management Protocol – Chemotherapy – Chronic Myeloid Leukaemia

7. TREATMENT DEFINITIONS

Imatinib 400mg daily
Dasatinib 100mg daily
Nilotinib 400mg twice daily

Doses may be adjusted for patients presenting in accelerated phase or blast crisis following discussion at MDT.

Author: Signature: Date:

Chair: Signature: Date:
(on behalf of OHMMG)

This document is uncontrolled when printed

File Name: LK-02	Page 2 of 2	Date of Issue: July 2010 Review Date: July 2012
Issue No.: 01/10	Written by: Dr K Gelly	Authorised by: OHMMG